Low versus high dose erythropoiesis-stimulating agents in hemodialysis patients with anemia: A randomized clinical trial

A Randomized, Placebo-Controlled Trial of Pentoxifylline on Erythropoiesis-Stimulating Agent Hyporesponsiveness in Anemic Patients With CKD: The Handling Erythropoietin Resistance With Oxpentifylline (HERO) Trial

(2015) David W. Johnson et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Erythropoiesis-Stimulating Agents: Dose and Mortality Risk

(2015) Guido Bellinghieri et al.   JOURNAL OF RENAL NUTRITION

Meta-analysis: Erythropoiesis-Stimulating Agents in Patients With Chronic Kidney Disease

(2013) Suetonia C. Palmer   ANNALS OF INTERNAL MEDICINE

Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: the clinical evaluation of the dose of erythropoietins (C.E. DOSE) trial protocol

(2012) Giovanni FM Strippoli et al.   Trials

High doses of epoetin do not lower mortality and cardiovascular risk among elderly hemodialysis patients with diabetes

(2011) Yi Zhang et al.   KIDNEY INTERNATIONAL

Association between high-dose erythropoiesis-stimulating agents, inflammatory biomarkers, and soluble erythropoietin receptors

(2011) Jula K Inrig et al.   BMC Nephrology

The Impact of Selecting a High Hemoglobin Target Level on Health-Related Quality of Life for Patients With Chronic Kidney Disease

(2009) Fiona M. Clement et al.   ARCHIVES OF INTERNAL MEDICINE

A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease

(2009) Marc A. Pfeffer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis

(2009) Bengt C. Fellström et al.   NEW ENGLAND JOURNAL OF MEDICINE

Secondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomes

(2008) Lynda A. Szczech et al.   KIDNEY INTERNATIONAL